Observational studyIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Economic burden borne by patients due to diagnostic delays in inflammatory bowel disease: Insights from a survey of newly diagnosed patients.
Observational study in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePatients with inflammatory bowel disease (IBD) often experience diagnostic delays owing to the absence of a definitive test. In our country, it is compounded by difficulty in differentiating it from tuberculosis, in certain situations. Hence, we decided to specifically estimate the economic burden that patients with IBD must bear until definitive treatment is initiated.
methodsThis prospective observational study included all consecutive patients with newly diagnosed IBD aged 18 years or older from October 2021 to December 2024. Details regarding symptom onset, investigations and treatments were collected using a structured questionnaire. Details regarding direct medical, direct non-medical and indirect costs were collected.
resultsNinety-seven patients, mean age 38.7 ± 13.5 years, median symptom duration 15 (7-38.5) months, were included in this study. Crohn's disease (CD) and ulcerative colitis (UC) were present in 55 (56.7%) and 42 (43.3%) patients, respectively. The median (interquartile range [IQR]) per capita monthly household income of the study population in rupees (Rs) was 5000 (3333-12,250). The economic burden due to diagnostic delay was Rs 136,029 (81,863-213,979), which amounted to 5.5 (2.3-9.2) times the monthly household income. The total direct medical, direct non-medical and indirect costs were Rs 69,610 (39,297-110,809), Rs 26,400 (14,238-45,340) and Rs 24,000 (10500-58210), respectively. The diagnostic delay for patients with CD was 3.4 times greater than that for patients with UC (27 [12-60] months vs. 8 [3-20] months; p < 0.001). Patients with CD suffered a greater economic burden than UC patients (Rs 162,750 [116,618-287,630] vs. Rs 96,752 [57,555-145,671]; p < 0.001) and required more visits to the doctor before the diagnosis was made (9 [7-14] vs. 5 [4-8.25]; p < 0.001).
conclusionThe economic burden of diagnostic delays in patients with IBD is a major problem. Patients with CD experienced longer delays, had more hospital visits and spent more money prior to the initiation of disease-specific therapy than those with UC.
Indexed as
Identifiers
40682729What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.